The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
Open accessAbstract
Objectives The purpose of this study was to estimate the effect of long-term exposure to lower plasma low-density lipoprotein cholesterol (LDL-C) on the risk of coronary heart disease (CHD).Background LDL-C is causally related to the risk of CHD. However, the association between long-term exposure to lower LDL-C beginning early in life and the risk of CHD has not been reliably quantified.Methods We conducted a series of meta-analyses to estimate the effect of long-term exposure to lower LDL-C on the risk of CHD mediated by 9 polymorphisms in 6 different genes. We then combined these Mendelian randomization studies in a meta-analysis to obtain a more precise estimate of the effect of long-term exposure to lower LDL-C and compared it with the clinical benefit associated with the same magnitude of LDL-C reduction during treatment with a statin.Results All 9 polymorphisms were associated with a highly consistent reduction in the risk of CHD per unit lower LDL-C, with no evidence of heterogeneity of effect (I(2) = 0.0%). In a meta-analysis combining nonoverlapping data from 312,321 participants, naturally random allocation to long-term exposure to lower LDL-C was associated with a 54.5% (95% confidence interval: 48.8% to 59.5%) reduction in the risk of CHD for each mmol/l (38.7 mg/dl) lower LDL-C. This represents a 3-fold greater reduction in the risk of CHD per unit lower LDL-C than that observed during treatment with a statin started later in life (p = 8.43 × 10(-19)).Conclusions Prolonged exposure to lower LDL-C beginning early in life is associated with a substantially greater reduction in the risk of CHD than the current practice of lowering LDL-C beginning later in life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, genetic variants reflect the effect of lifelong changes in ApoB-containing lipoproteins on the risk of cardiovascular disease, which appear to be cumulative over time.5,34”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredIn the citing paper
“Numerous epidemiological studies, Mendelian randomization studies, and RCTs have consistently demonstrated a log-linear relationship between the absolute changes in plasma LDL-C and the risk of ASCVD [34,45-50].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [47]
In the citing paper
“Additionally, increasing evidence also suggests that the duration of exposure to low LDL-C levels may be as important as the magnitude of LDL-C lowering [11][12][13][14][15][16].”
In the citing paper
“A large meta-analysis by Ference et al. has demonstrated that prolonged exposure to lower LDL-C levels beginning at a young age is associated with a substantially greater reduction in the risk of CVD than the current practice of lowering LDL-C levels later in life [13].”
In the citing paper
“It was found that lifelong exposure to low LDL-C levels as a result of these gene polymorphisms was associated with three-fold greater reduction in the risk of CVD per unit lower LDL-C level than that observed during treatment with a statin started later in life.”
In the citing paper
“The long-term follow-up of large clinical trials of statins that were conducted in the 1990s, such as the West of Scotland Coronary Prevention Study (WOSCOPS) and the Heart Protection Study (HPS)628, 629) confirmed that early initiation of LDLC-lowering therapy regardless of the plasma LDL-C level was useful for the long-term prevention of cardiovascular events and all-cause mortality in high-risk”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [628]
In the citing paper
“No increases in new-incidence cancer or non-CVD deaths were observed, which reconfirms the safety of long-term LDL-C-lowering therapy using statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [628]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies (2011) · Nature · doi:10.1038/nature10405 · Cited by 2,033
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 901
Ros, E., Kastelein, J. J. P., Blom, D. J., & Deanfield, J. E. (2014) · Cited by 1
What does the future hold for cholesteryl ester transfer protein inhibition?
Arsenault, B. J., Boyer, M., & Kastelein, J. J. P. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000248 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
Extrem niedrige LDL-Cholesterinkonzentrationen durch moderne lipidsenkende Therapien
Schettler, V. J. J., Roeseler, E., Platzer, C., Thode, C., Schettler, E., Grützmacher, P., Julius, U., & Klingel, R. (2017) · CardioVasc · doi:10.1007/s15027-017-1186-x · Cited by 1
Bubnova, M. G. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-6-191-201 · Cited by 1
Nutrition Versus Statins in Primary Prevention: Where do we Stand Now?
Zabetakis, I., Lordan, R., & Τσούπρας, Α. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00009-4 · Cited by 1
Guia prático para a utilização dos inibidores da PCSK9 em Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.05.005 · Cited by 6
Estado autonómico y poder judicial
Mestre, J. B. I. (2002) · Dialnet (Universidad de la Rioja) · Cited by 1
Epidemiology of Atherosclerotic Vascular Diseases
Andersson, C., & O’Donnell, C. J. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_46 · Cited by 1
Neue Optionen zur Intensivierung der lipidsenkenden Therapie
Baessler, A., & Fischer, M. (2022) · Herz · doi:10.1007/s00059-022-05111-z · Cited by 1
Epidemiology of Cardiovascular Disease in Children
Gidding, S. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-31107-4_13 · Cited by 1
Ki, Y., Han, S.-J., Cha, T., Lee, J. H., Seo, E. K., Yang, J. W., Hwang, W. M., Jin, D., Park, J., Ryu, H. Y., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236949 · Cited by 1
Bashir, B., Iqbal, Z., Schofield, J. D., & Soran, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00012-7 · Cited by 1
Severance, L. M., Pack, J. D., Contijoch, F. J., & McVeigh, E. R. (2023) · Medical Physics · doi:10.1002/mp.16652 · Cited by 1
Mottola, G., Welty, F. K., Mojibian, H. R., & Faridi, K. F. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1272944 · Cited by 1
Masana, L., Moya, G. D., de Isla, L. P., Plana, N., Andreychuk, N., Ortiz, M. R., Herrera, N., Gómez‐Doblas, J. J., Capitán, J. R., Garcia, R. V., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.09.022 · Cited by 1
Chen, Y., Zhang, S., Tao, Y., Hu, W., Li, D., Shen, X., Li, Y., Lin, M., Zhang, W., Liu, X., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1254125 · Cited by 1
Polymorphisms of APOE and APOB genes and dyslipidemias in a South Brazilian Cohort
Gasparin, C. C., Tureck, L. V., Ferrari, L. P., de Souza, R. L. R., & Alle, L. F. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n1p992-1012 · Cited by 1
Confluence of Mendelian Randomization with Clinical Trials as To Very Low Levels of LDL Cholesterol
Chacra, A. P. M., Saldanha, A. L. R., Margeotto, A. P. P., Gasparoto, A. L. V., Ampuero, M. S. S., Castro, L. F. D., & Martinez, T. L. D. R. (2024) · Clinical Medicine And Health Research Journal · doi:10.18535/cmhrj.v4i1.304 · Cited by 1
Minotti, G., & Camilli, M. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001963 · Cited by 1
Clinical impact of genetic testing for lipid disorders
Muzurović, E. M., Borozan, S., & Rizzo, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001133 · Cited by 1
Association between Maternal LDL Level during Pregnancy and Offspring LDL Level at Age 8
Oishi, T., Mitsuda, N., Watanabe, K., Araki, M., Nagai, R., Eitoku, M., Fujieda, M., Suganuma, N., & Japan Environment and Children’s Study (JECS) Group (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j052 · Cited by 1
Association Between CYP2D7 and TCF20 Polymorphisms and Coronary Heart Disease
Zhang, W., Wan, P., Zhang, M., Chang, Y., Du, S., Jin, T., & Wang, Y. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09907-9 · Cited by 1
Genetic Risk Score Enables a Vaccine for Early Primary Prevention of CAD
Roberts, R. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1617 · Cited by 1
Михайловна, А. А., Анатольевич, К. В., & Kuznetsov, V. I. (2017) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2017-21-1-29-34 · Cited by 1
\tJair Baron Junior1, M. B. (2018) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2018.11.00368 · Cited by 1
L’hypercholestérolémie familiale
Bruckert, É., & Gallo, A. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30398-x · Cited by 2
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Παναγιωτοπούλου, Ό., Chiesa, S. T., Tousoulis, D. M., & Charakida, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190827151012 · Cited by 1
Veloso, R. C. D. S. G., Cruzeiro, M. G. M., Dias, B. M., & Reis, A. M. M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1793313 · Cited by 1
Begründung für die neuen LDL-Cholesterin-Zielwerte
Otto, S., Schulze, P. C., & Weingärtner, O. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1200-1322 · Cited by 1
PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection
Pandey, P., Zhao, C., & Liu, B. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0904-0_12 · Cited by 1
Burlova, N. G. (2020) · Medsestra (Nurse) · doi:10.33920/med-05-2003-04 · Cited by 1
Ferrari, D., Motta, A., Strollo, M., & Locatelli, M. (2020) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v91i3.8980 · Cited by 1
Coronary angiographic profile in Egyptian patients with xanthelasma palpebrarum
Hassanin, N., Bakhoum, S., & Saraya, M. (2020) · Kasr Al Ainy Medical Journal · doi:10.4103/kamj.kamj_30_20 · Cited by 1
Soška, V. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.005 · Cited by 1
Addressing Nutritional Gaps: Simple Steps for the Primary Care Provider
Quan, Q. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0059 · Cited by 1
An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome
Lacy (2020) · The Journal of Family Practice · doi:10.12788/jfp.0060 · Cited by 1
Soška, V., Karásek, D., Blaha, V., Cífková, R., Freiberger, T., Kraml, P. J., Pitha, J. V., Rosolová, H., Štulc, T., Urbanová, Z., et al. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.160 · Cited by 1
Epidemiology of Cardiovascular Disease in Children
Gidding, S. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-824-9_12 · Cited by 1
Michos, E. D., Martin, S. S., & Blumenthal, R. S. (2016) · Circulation · doi:10.1161/circulationaha.115.020948 · Cited by 1
Phytosterols and blood lipid risk factors for cardiovascular disease
Ras, R. T. (2014) · doi:10.18174/317016 · Cited by 1
Noordam, R., Bos, M. M., Wang, H., Winkler, T. W., Bentley, A. R., Kilpeläinen, T. O., de Vries, P. S., Sung, Y. J., Schwander, K., Cade, B. E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/559393 · Cited by 1
Tratar la dislipemia, algo más que dar estatinas
Masana, L. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.03.003 · Cited by 1
Wang, Z., Xiao, Y., Huang, W., Zou, C., Lu, J., Zhang, J., Han, L., Jiao, F., Tian, D., Jiang, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4045947 · Cited by 1
Lipid management in older patients
Mendys, P., Simpson, R. J., & Sadaf, M. I. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107294967.031 · Cited by 1
(2015) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.12.4.101corr1 · Cited by 1
Detection and Stabilization of Vulnerable Plaques in the Coronary ArteriesPreprint
Бикбаева, Г. Р., Kovalskaya, A. N., Rodin, A., Pavlova, T. V., & Duplyakov, D. V. (2023) · Preprints.org · doi:10.20944/preprints202307.1557.v1 · Cited by 1
Yang, G., Mason, A. M., Wood, A., Schooling, C. M., & Burgess, S. (2023) · medRxiv · doi:10.1101/2023.09.27.23296203 · Cited by 1
Janeczek, M., Korbel, R., Janeczek, F., Alber, H., Küchenhoff, H., & Rinder, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.03.626694 · Cited by 1
Verhulst, B., Harris, J., Adams, A. M., Benstock, S. E., Tong, C. W.-C., Case, A. J., & Hettema, J. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.04.703692 · Cited by 1
Maki, K. C., & Duell, P. B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.022 · Cited by 1
Novel lipid derivatives for health benefits
Madawala, S. R. P. (2013) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences))
Nilsson, P. M. (2013) · PubMed
Gotto, A. M. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.10.020
Rees, A. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.003
Paixao, A. R. M., & Berry, J. D. (2013) · Journal of Nuclear Cardiology · doi:10.1007/s12350-013-9834-8
If the wheel ain’t broke, don’t reinvent it
Ohukainen, P. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-51
Maretty, L., Sibbesen, J. A., & Krogh, A. (2014)
Novel Lipid Derivatives for Health
Madawala, S. R. P. (2013)
Statine fast für jeden, aber individualisiert
Bischoff, A. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-7517-x
Lower LDL Cholesterol Level and Risk for CHD Later in Life
Fleischmann, K. E. (2012) · Journal watch · doi:10.1056/jw201211060000009
Wilson, D. P., de la Torre, A., Brautbar, A., & Hamilton, L. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1189824
Frühere Zulassung von Arzneimitteln - Eine Chance für Patienten?
Paar, W. D. (2016) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2016.04.010
Cholesterinsenkung zur kardiovaskulären Prävention
Windler, E. E. T., & Zyriax, B. (2016) · Der Gynäkologe · doi:10.1007/s00129-016-3853-x · Cited by 1
Causal Inference in Medicine via Mendelian Randomization
Frayling, T. M., & Voight, B. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_24
Parhofer, K. G. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-7653-y
Modell zum individualisierten Lipidmanagement
Weingärtner, O., Lütjohann, D., & Elsässer, A. (2016) · Der Kardiologe · doi:10.1007/s12181-016-0054-8
Supplementierung von Phytosterinen
Windler, E. E. T., Zyriax, B., & Beil, F. U. (2015) · CardioVasc · doi:10.1007/s15027-015-0777-7
Statins for All Patients with Hypertension—It is still not Prime Time!
Desai, N., & Venkatesh, C. R. (2016) · Hypertension Journal · doi:10.5005/jp-journals-10043-0029
Genetic Susceptibility to Cardiovascular Diseases
Briasoulis, Α. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00007-0
Bruckert, É. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30137-7
Godina 2015. u kardiologiji: prevencija The year in cardiology 2015: prevention
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016)
Gibt es eine „untere Grenze“ beim LDL-C?
Leitolf, H., & Klose, G. (2016) · CardioVasc · doi:10.1007/s15027-016-1031-7
Analysis of genetic aspects of therapy with Rosuvastatin
Kozhakhmetov, S., Kushugulova, A. R., Kakimova, A. B., Nurgozhin, T. S., & Zhumadilov, Z. S. (2016) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/1812-2892-2016-2-22-26
Hitting Hard and Early: A Novel Paradigm for Lipid Lowering in Primary Prevention
Lautsch, D., & Gitt, A. K. (2018) · Cardiology · doi:10.1159/000488972
Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?
Bansal, M., & Agarwala, R. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.06.010
Primary Prevention of Atherosclerotic Cardiovascular Disease
Robinson, J. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00028-5 · Cited by 1
Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines
Djordjevic, D. B., Đorđević, A. D., & Lović, D. B. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00173-w
Lifestyle intervention strategies for diabetes management
Tay, J., & Tay, J. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.25909/5b63b9ac0685f
Rehman, S., Ahmad, T. M., Hayat, A., & Tahir, S. (2019) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.35.4.1308
General Discussion and Future Perspectives
Cassarini, C. (2019) · CRC Press eBooks · doi:10.1201/9780429448300-7
Shah, S. N., Rajagopal, N. P., Shah, B., Biswas, A. D., Hiremath, J., & Bansal, R. (2018) · PubMed
Encouragement of Super-aggressive LDL-lowering Therapies
Tada, H., Sakata, K., Takamura, M., & Kawashiri, M. (2019) · Journal of Coronary Artery Disease · doi:10.7793/jcad.25.19-00005
The role of carotid artery disease in ischaemic stroke
Ball, S. (2019) · Research Explorer (The University of Manchester)
Statin adherence and LDL-C reduction in a pediatric population
Enright, C., Peterson, A. L. H., Eickhoff, J. C., & Dodge, A. (2020) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2020.101210 · Cited by 1
Very special case of primary prevention with statins
Pang, J., Martin, A., & Watts, G. F. (2020) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.14798
Hot Topics in Primary Care 2020 Introduction
Brunton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0058
The Low-Density Lipoprotein Cholesterol Hypothesis: An Update
Rengarajan, R., Tecson, K. M., & McCullough, P. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_7
Bubnova, M. G. (2017) · Cardiosomatics · doi:10.26442/cs45373
Genetic risk stratification enables primary prevention of CAD
Roberts, R., & Chang, C. C. (2020) · Journal of Integrative Cardiology · doi:10.15761/jic.1000298
Finalement, jusqu’où faut-il baisser le LDL-cholestérol et comment ?
Béliard, S. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.011
Corral, P., López, A. A. P., Giunta, G. A., Buitrago, A. F., & Saraiva, J. F. K. (2021) · doi:10.22541/au.161548923.32347892/v1
Review of LDL-C Lowering with Focus on New and Emerging Agents
Brinton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0070
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician
Bakris (2020) · The Journal of Family Practice · doi:10.12788/jfp.0072
A New Era in Asthma Management: Assessment of Asthma Control
Murphy, M. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0061
Davies., 尼., 迈克尔五福尔摩斯, & 乔治戴维斯史密斯 (2018)
Hypercholesterolemia at a young age
Spiridonov, A. N., & Ragino, Y. I. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-17-2-83-93
Metadata
- Authors
- Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M.
- Affiliations
- Wayne State University (US)
- University of Tennessee Health Science Center (US)
- Detroit Medical Center (US)
- Corresponding author
- Ference, Brian A.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 60
- Issue
- 25
- Pages
- 2631-2639
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W72392028
- Cited by
- 898
- References
- 44
- Citations by year
- 2026: 69 · 2025: 61 · 2024: 65 · 2023: 80 · 2022: 64 · 2021: 69 · 2020: 81 · 2019: 74 · 2018: 55 · 2017: 48 · 2016: 82 · 2015: 67 · 2014: 41 · 2013: 37 · 2012: 2
- FWCI
- 47.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- Medtronic
- NIH
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- LDL cholesterol, coronary heart disease risk, genetic polymorphism, Mendelian randomization, statin therapy, LDL cholesterol lowering, cardiovascular risk reduction
- MeSH terms
- Coronary Artery Disease, Follow-Up Studies, Genetic Markers, Humans, Cholesterol, LDL, Polymorphism, Genetic, Risk Factors, Time Factors, Global Health, Incidence, Risk Assessment, Genetic Predisposition to Disease, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
